January 21, 2021

The Niche

Trusted stem cell blog & resources

Month: June 2017

3 min read

Hans Keirstead is one of the top stem cell scientists in the world who has been doing cutting edge research including on using stem cells to reverse paralysis where he teamed up with super patient advocate Roman Reed (see the two pictured at right), but now he is also running for Congress. How cool is that? Here is a quick Q&A interview with Hans today (see below). Please consider making a campaign contribution to support his candidacy. He would be amazing as a Congressman! When did …Read More

2 min read

I’ve always grown tomatoes in my garden and I like unusual varieties. This year I’ve got a bunch of cool tomatoes growing out back. Some are now starting to ripen so it’s getting more exciting. Note that this posted has been updated for 2020. Growing tomatoes is not as hard as I thought originally, but there are some tricks. I’m going to do a separate post fully on tomato growing tips. Some key ones are pick the sunniest spot in your yard, work on …Read More

2 min read

I’ve seen stem cell clinic ad after ad pop up in the mainstream media in my own hometown in The Sacramento Bee paper, but others are sprouting as well and a friend sent me a particularly striking stem cell advertisement from a recent copy of the San Francisco Chronicle. Not only does this stem cell clinic say you can come to a free stem cell seminar, but also you get a free lunch and $1,000 off a stem cell “treatment” of some kind if you …Read More

6 min read

Are designer babies made using CRISPR or other genetic modification technologies closer to reality today? If so, what exactly should we do about it? Researchers can use CRISPR to genetically modify just about any organism or its cells, but targeting humans is the subject of the most intense discussion including using CRISPR in the human germline for heritable “editing” or genetic modification of humans. This could in theory be done via human embryos or human germ cells with mostly existing technology. CRISPR studies on healthy human …Read More

4 min read

By Agnes Soos Amid the hustle and bustle of downtown Boston, nearly four thousand researchers and exhibitors gathered for the 15th Annual ISSCR Meeting. With presentations from over thirty plenary lectures, and dozens of others featured in concurrent sessions and the daily Innovation Showcases, there definitely was no shortage of exciting research to discover and discuss. There was a record number of exhibitors this year with over 150 companies set up in Exhibit Hall. Added to this, the always-busy Meet-Up Hubs, the job boards …Read More

3 min read

Can a stem cell clinic business get FDA RMAT designation? At least one announced it was trying, but now seems to have given up. Stem cell clinic business US Stem Cell, Inc. has reportedly announced that it is at least temporarily abandoning its efforts at getting Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The company’s penny stock $USRM has been gyrating for months and I had earlier wondered if could be some fake news about it. The USRM news now seems real and not …Read More

4 min read

By Cátia Bandeiras, PhD Student at University of Lisbon, Portugal and Massachusetts Institute of Technology. See tweets from the conference using #ISSCR2017 @apulgarita I just wrapped up my stay at the Annual Meeting of ISSCR 2017, which happened in Boston. I decided to take advantage of the fact that I am living in Boston at the moment and go to the largest stem cell research conference to present my work. As a matter of fact, I am not the usual PhD student in stem …Read More

3 min read

The idea of CIRM as a dedicated state stem cell agency was one of the things that got me excited about starting my time as a professor doing research on stem cells in California way back in 2005-2006 on the job hunt. Fast forwarding to today now 11 years later, CIRM is still on the cutting edge, but some major things have changed for California’s stem cell agency and as it looks to its future, the questions and challenges are different too. By analogy, …Read More

3 min read

In December of each year I make a list of stem cell predictions for the coming year, and I made 20 such predictions for 2017 so I’m wondering how I’m doing so far on these now that it’s June. Below is my work-in-progress scorecard for these so far. Positive news from Asterias on trial for stem cell-based therapy for spinal cord injury. Status: Correct, trial looking encouraging. Upbeat news from ViaCyte on stem cell-based therapy trial for diabetes. Status: Correct, raising $10M and things looking promising. More positive news …Read More

2 min read

Many stem cell clinics are in a bind in 2017 in the new RMAT approval reality. Stem cell clinics say that they only want to help people by providing stem cell therapies to patients in a speedier way that they claim getting FDA approval for a trial just doesn’t allow, but that doesn’t ring true. It never has and now even less so. The new RMAT designation out there based on the 21st Century Cures Act whereby the FDA can rapidly accelerate truly promising …Read More